APR 01, 2021 8:00 AM PDT

Develop High Quality Therapeutic Antibodies Straight From Selections in Record Time

Sponsored by: Carterra
C.E. Credits: P.A.C.E. CE Florida CE
  • Chief Scientific Officer at Specifica

      Andrew Bradbury is Chief Scientific Officer of Specifica, a company he founded in 2016, after retiring as Group Leader at LANL. He trained in medicine at the Universities of Oxford and London and received his PhD from the University of Cambridge at the MRC Laboratory of Molecular Biology, under the guidance of Cesar Milstein. He has worked in antibody engineering for over thirty years. Specifica's mission is to provide companies developing therapeutic antibodies with the worlds best antibody selection platform.

    • Technical Product Manager at Carterra

        Noah T. Ditto is the Technical Product Manager at Carterra. Prior to joining Carterra in 2014, Noah supported Drug Discovery and Early Clinical Development for nearly a decade at Bristol-Myers Squibb in Princeton, NJ with a focus on biophysical characterization of protein and peptide-based biomarkers, drug targets, and therapeutics. Noah earned his MS from The Pennsylvania State University developing chromatography-based fractionation techniques to isolate relevant serum biomarkers in Dengue infection and his MBA at West Chester University concentrating on Business Analytics.


      Date:  April 01, 2021

      Time: 8:00am (PDT),  11:00am (EDT)


      During the COVID-19 pandemic, new technologies have enabled the biopharmaceutical industry to develop therapeutic antibodies fast. The Carterra LSA provides researchers with the screening and characterization throughput and functionality needed to match the output from today’s state-of-the-art antibody expression platforms. This enables all antibodies to be rapidly and comprehensively screened early in the discovery process so that unique epitopes and potential novel therapeutic candidates can be identified.

      Andrew Bradbury PhD, Chief Scientific Officer of Specifica will discuss their next-generation antibody library platform that provides robust antibody diversity and delivers superior therapeutics. Andrew discusses how Carterra’s high throughput kinetics and epitope binning technologies enable the rapidly discovery of SARS-CoV-2 neutralizing antibodies.

      Noah T. Ditto, Technical Product Manager at Carterra will discuss how high throughput Surface Plasmon Resonance (HT-SPR) facilitates a paradigm shift in antibody screening and characterization—now discover therapeutic candidates in days vs. months.


      Learning objectives:

      • Rapidly characterize large panels of antibodies for kinetics, affinity, and epitope diversity.
      • Obtain high quality data directly from crude supernatants.
      • Accelerate library-to-lead triage.
      • Build your IP portfolio.



      Webinars will be available for unlimited on-demand viewing after live event.

      Show Resources
      Show Resources
      • See more